Zhejiang University: Marine Compound THK01 Shows Promise for IBD Treatment
Researchers at Zhejiang University have isolated a deep-sea marine compound from the Mariana Trench that demonstrated significant anti-inflammatory potency in preclinical inflammatory bowel disease models at one-tenth of the dosage required by standard first-line therapies, according to a report published by Zhejiang Daily.
Key Clinical Takeaways:
- The deep-sea compound THK01 showed superior therapeutic efficacy at 30 mg/kg compared to standard clinical treatments administered at 300 mg/kg in animal models.
- Isolated from marine actinomycetes gathered from a depth of 10,000 meters, the project has completed preclinical efficacy testing and is seeking capital investment for clinical trials.
- The Zhoushan Science and Technology Bureau classified the project as a key municipal scientific and technological project in 2026 to support artificial intelligence-driven structural optimization.
Deep-Sea Microbial Discovery from Ten Thousand Meters
Inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease, affect more than ten million patients globally. Current therapeutic interventions rely heavily on aminosalicylates, immunosuppressants, and biologics. However, these standard treatments frequently involve high recurrence rates, limited response rates in subsets of patients, and significant long-term side effects. Using a self-developed deep-sea hydrothermal sampler deployed alongside the submersible Fendouzhe, researchers recovered microbial samples from the Mariana Trench. From a collection of over 30,000 deep-sea microorganisms, the team isolated thousands of compounds to establish a marine compound library.
Preclinical Efficacy and Structural Optimization of THK01
The resulting candidate molecule, designated THK01, originates from the metabolic products of marine actinomycetes living under high salinity, high pressure, low temperature, and darkness. In preclinical testing using murine models of inflammatory bowel disease, the compound exhibited a profound dose advantage. A dosage of 30 mg/kg achieved superior therapeutic outcomes relative to conventional first-line agents administered at 300 mg/kg. To accelerate structural refinement, the Zhoushan Science and Technology Bureau designated the project for municipal key scientific and technological funding in 2026, facilitating artificial intelligence-driven molecular iteration.
THK01 Requires Hundred-Million-Yuan Capital for Clinical Trials
Prior research phases for THK01 secured over 5 million yuan through the National Natural Science Foundation, the Zhejiang “Lingyan” provincial project, and corporate research grants. Speaking at a Ministry of Natural Resources industry roadshow, Ma Zhongjun indicated that transitioning the compound into human clinical trials requires scaling capital expenditures from the million-yuan tier to the hundred-million-yuan tier. The research team currently plans to release approximately 20 percent of company equity to secure industrial capital for upcoming clinical evaluations, structural optimization, and manufacturing scale-up. Market pressures compound these clinical ambitions, as current biologic therapies incur annual expenses ranging from tens of thousands to over one hundred thousand yuan for Chinese patients. The emergence of a low-dose, orally administered small-molecule drug derived from deep-sea bioresources aims to alleviate this economic burden while expanding therapeutic alternatives.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.